Genetically altering the immunomodulatory effects of mesenchymal stem cells (MSCs) in order to increase the expression of interleukin-12 and interleukin-17 can help to alter the “inflamed” tumor microenvironment and also help activate CAR T-cells against tumor cells [134]. The gene discussed is IL17A; the disease is neoplasm.